Status:
COMPLETED
Acupuncture for Peripheral Neuropathy Induced by Paclitaxel in Early Stage Breast Cancer
Lead Sponsor:
Instituto Brasileiro de Controle do Cancer
Conditions:
Peripheral Neuropathy Due to Chemotherapy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The present study aims to evaluate the effectiveness of acupuncture in the treatment of chemotherapy drug paclitaxel induced peripheral neuropathy in patients with early stage breast cancer
Detailed Description
Patients with early stage breast cancer (stages I,II,III) who received paclitaxel in neoadjuvant or adjuvant chemotherapy protocol and developed peripheral neuropathy will be randomized to receive tru...
Eligibility Criteria
Inclusion
- Age \>= 18 years old.
- Agreed to sign the Informed Consent Term
- ECOG 0-1
- Breast cancer stages I, II and III.
- Received adjuvant or neoadjuvant chemotherapy containing weekly paclitaxel 80 mg/m2.
- Peripheral sensory neuropathy grade 2 and 3 by the "Common Terminology Criteria for Adverse Events" (CTCAE) v5.0
Exclusion
- Previous history of peripheral neuropathy due to other comorbidities.
- Prior treatment with chemotherapy for cancer other than breast cancer.
- Use of medications to treat peripheral neuropathy.
- Metastatic disease.
- Presence of lymphedema of any degree.
- History of coagulopathy or full anticoagulation.
- Previous acupuncture treatment for any indication within the last 90 days.
Key Trial Info
Start Date :
January 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 26 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04461977
Start Date
January 30 2020
End Date
March 26 2024
Last Update
May 31 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Brasileiro de Controle de Cancer (IBCC Oncologia)
São Paulo, São Paulo, Brazil, 03102-006